Eloxx Pharmaceuticals (ELOX) Q1 2026 earnings summary

Executive summary

• Focused on advancing exaluren for rare kidney diseases and ZKN-013 (licensed to Almirall) for rare skin diseases, with ongoing and planned clinical trials for both programs.

• Completed a Phase 2a trial for exaluren in Alport Syndrome, showing promising biomarker improvements; Phase 2b trial to start in 2026.

• ZKN-013 licensed to Almirall, with potential milestone and royalty payments up to $470 million.

Financial highlights

• Net loss of $3.8 million for Q1 2026, compared to $1.7 million in Q1 2025.

• Operating expenses increased to $3.8 million from $1.2 million year-over-year, driven by higher R&D and G&A costs.

• Cash and cash equivalents were $6.4 million as of March 31, 2026.

• Accumulated deficit reached $304.3 million.

Outlook and guidance

• Cash on hand is insufficient to fund operations for the next twelve months; substantial doubt exists about ability to continue as a going concern.

• Plans to initiate Phase 2b trial for exaluren in 2026 and a Phase 2 trial for nmADPKD in 2027.

• Management intends to seek additional capital through equity, debt, or strategic partnerships.